Carolina de Oliveira Cruz Latorraca

Carolina de Oliveira Cruz Latorraca

Auto-generated profile, based on publicly available information

Carolina de Oliveira Cruz Latorraca

Centro Universitário São Camilo, Medicine São Paulo Brazil

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2019 in Journal of Child Neurology
Verified
Journal Article
Closed access
PDF file
MZMárcia Andréa Zanon
Márcia Andréa Zanon
RPRafael Leite Pacheco
Rafael Leite Pacheco
CLCarolina de Oliveira Cruz Latorraca
Carolina de Oliveira Cruz Latorraca
AMAna Luiza Cabrera Martimbianco
Ana Luiza Cabrera Martimbianco
DPDaniela Vianna Pachito
Daniela Vianna Pachito
RRRachel Riera
Rachel Riera
Aim: To assess the effects of neurodevelopmental treatment for children with cerebral palsy. Methods: We conducted a systematic review following the recommendations of the Cochrane Handbook for Systematic Reviews of Interventions and reported in accordance to PRISMA Statement. Through a comprehensive literature search we considered all randomized clinical trials that compared neurodevelopmental treatment with conventional physical therapy for children with cerebral palsy. We used the Cochrane Risk of Bias Table to assess the risk of bias of the included randomized clinical trial, and the GRADE approach to evaluate the certainty of the body of the evidence. Results: We found 3 randomized clinical trials (2 published and 1 ongoing) comprising 66 children. Published randomized clinical trials presented methodological and reporting limitations and only 1 provided data for outcomes of interest. No difference between neurodevelopmental treatment and conventional physical therapy was found for gross motor function (mean difference 1.40; 95% confidence interval –5.47 to 8.27, low certainty evidence). Conclusion: This review found that the effects of neurodevelopmental treatment for children with cerebral palsy are still uncertain. Further studies are required to assess the efficacy and safety of neurodevelopmental treatment for this purpose and until there, current evidence do not support its routinely use in practice. Number of protocol registration in PROSPERO database: CRD42017082817 (available from https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=82817 ).

1 December 2020 in Journal of Evidence-Based Dental Practice
Verified
Journal Article
Closed access
GSGiovanna Marcílio Santos
Giovanna Marcílio Santos
RPRafael Leite Pacheco
Rafael Leite Pacheco
SBSandra KALIL BUSSADORI
Sandra KALIL BUSSADORI
ESElaine Marcílio Santos
Elaine Marcílio Santos
RRRachel Riera
Rachel Riera
AMAna Luiza Cabrera Martimbianco
Ana Luiza Cabrera Martimbianco

16 December 2019 in Trials
Verified
Journal Article
Open access
PDF file
VMVânia Mozetic
Vânia Mozetic
LLLetícia Leonel
Letícia Leonel
RPRafael Leite Pacheco
Rafael Leite Pacheco
CLCarolina de Oliveira Cruz Latorraca
Carolina de Oliveira Cruz Latorraca
TGTaís Guimarães
Taís Guimarães
RRRachel Riera
Rachel Riera
Background: A considerable amount of randomized controlled trials (RCTs) have been published on statins and/or fibrates for diabetic retinopathy, a clinical condition associated with high social and economic burden. Adherence to the CONSORT statement items is imperative to ensure transparency and reproducibility in clinical research. The aim of this study is to assess the reporting quality and the adherence to CONSORT of RCTs assessing statins and/or fibrates for diabetic retinopathy. Methods: We conducted a critical appraisal study at Discipline of Evidence-based Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo (Unifesp). A sensitive literature search was performed to identify all relevant RCTs, with no time or language limits. Two authors independently evaluated the reporting quality of the selected RCTs using the CONSORT statement as a standard. Results: Thirteen reports of RCTs were included in this study. The adherence of the reports to CONSORT items ranged from 24% to 68%. The median score was 11 (interquartile range (IQR) 8 to 13). When analyzed separately, the methods sections of the reports had a median of three items (IQR 2 to 4) judged adherent to the methods items of CONSORT (items 3 to 12). The most underreported items were those related to trial design, title and abstract, allocation concealment, implementation of the randomization sequence, and blinding. Other important items, such as the one related to the description of the inclusion criteria, also had low adherence. Conclusions: The overall adherence to the CONSORT checklist items was poor, especially in the items related to the methods section. RCT reports on statins and/or fibrates for diabetic retinopathy must be optimized to avoid reporting biases and to improve transparency and reproducibility.

10 July 2023 in Health Research Policy and Systems
Verified
Journal Article
Open access
PDF file
RRRachel Riera
Rachel Riera
CLCarolina de Oliveira Cruz Latorraca
Carolina de Oliveira Cruz Latorraca
RPRoberta Carreira Moreira Padovez
Roberta Carreira Moreira Padovez
RPRafael Leite Pacheco
Rafael Leite Pacheco
DRDavi Mamblona Marques Romão
Davi Mamblona Marques Romão
AMAna Luiza Cabrera Martimbianco
Ana Luiza Cabrera Martimbianco
Background: Health evidence needs to be communicated and disseminated in a manner that is clearly understood by decision-makers. As an inherent component of health knowledge translation, communicating results of scientific studies, effects of interventions and health risk estimates, in addition to understanding key concepts of clinical epidemiology and interpreting evidence, represent a set of essential instruments to reduce the gap between science and practice. The advancement of digital and social media has reshaped the concept of health communication, introducing new, direct and powerful communication platforms and gateways between researchers and the public. The objective of this scoping review was to identify strategies for communicating scientific evidence in healthcare to managers and/or population. Methods: We searched Cochrane Library, Embase®, MEDLINE® and other six electronic databases, in addition to grey literature, relevant websites from related organizations for studies, documents or reports published from 2000, addressing any strategy for communicating scientific evidence on healthcare to managers and/or population. Results: Our search identified 24 598 unique records, of which 80 met the inclusion criteria and addressed 78 strategies. Most strategies focused on risk and benefit communication in health, were presented by textual format and had been implemented and somehow evaluated. Among the strategies evaluated and appearing to yield some benefit are (i) risk/benefit communication: natural frequencies instead of percentages, absolute risk instead relative risk and number needed to treat, numerical instead nominal communication, mortality instead survival; negative or loss content appear to be more effective than positive or gain content; (ii) evidence synthesis: plain languages summaries to communicate the results of Cochrane reviews to the community were perceived as more reliable, easier to find and understand, and better to support decisions than the original summaries; (iii) teaching/learning: the Informed Health Choices resources seem to be effective for improving critical thinking skills. Conclusion: Our findings contribute to both the knowledge translation process by identifying communication strategies with potential for immediate implementation and to future research by recognizing the need to evaluate the clinical and social impact of other strategies to support evidence-informed policies. Trial registration protocol is prospectively available in MedArxiv (doi.org/10.1101/2021.11.04.21265922).

18 September 2022 in European Journal of Haematology
Verified
Journal Article
Closed access
DPDaniel M. Pasqui
Daniel M. Pasqui
CLCarolina D. O. C. Latorraca
Carolina D. O. C. Latorraca
RPRafael L. Pacheco
Rafael L. Pacheco
RRRachel Riera
Rachel Riera

5 March 2021 in Sports Health: A Multidisciplinary Approach
Verified
Journal Article
Open access
PDF file
RFRaphael Einsfeld Simões Ferreira
Raphael Einsfeld Simões Ferreira
RPRafael Leite Pacheco
Rafael Leite Pacheco
CLCarolina de Oliveira Cruz Latorraca
Carolina de Oliveira Cruz Latorraca
RRRachel Riera
Rachel Riera
RERicardo Guilherme Eid
Ricardo Guilherme Eid
AMAna Luiza Cabrera Martimbianco
Ana Luiza Cabrera Martimbianco
Context: Caffeine is 1 of the most popular supplements consumed by athletes, and the evidence for improving soccer performance remains limited. Objective: To investigate and update the effects (benefits and harms) of caffeine to improve performance on soccer players. Data Sources: Electronic search in Medline (via PubMed), CENTRAL, Embase, SPORTDiscus, and LILACS, from inception to March 28, 2020. Study Selection: Randomized clinical trials (RCTs) assessing the effects of caffeine on the performance of soccer players. Study Design: Systematic review with meta-analysis. Level of Evidence: Level 1. Data Extraction: Data extraction was conducted independently by 2 authors using a piloted form. We assessed methodological quality (Cochrane risk-of-bias [RoB] table) and the certainty of the evidence (GRADE [Grading of Recommendations Assessment, Development and Evaluation] approach). Results: Sixteen RCTs were included. Overall methodological quality was classified as unclear to low risk of bias. When assessing aerobic endurance, meta-analyses did not demonstrate the differences between caffeine and placebo (mean difference [MD], 44.9 m; 95% confidence interval [CI], −77.7 to 167.6). Similarly, no difference was observed during time to fatigue test (MD, 169.8 seconds; 95% CI, −71.8 to 411.6). Considering anaerobic power, meta-analyses also did not find differences for vertical jump (MD, 1.01 cm; 95% CI, −0.68 to 2.69) and repeated sprint tests (MD, −0.02 seconds; 95% CI, −0.09 to 0.04), as well as reaction time agility test (MD, 0.02 seconds; 95% CI, −0.01 to 0.04) and rating of perceived exertion (MD, 0.16 points; 95% CI, −0.55 to 0.87). Regarding safety, a few minor adverse events were reported. Based on the GRADE approach, the certainty of this evidence was classified as very low to low. Conclusion: We found no significant improvement in soccer-related performance with caffeine compared with placebo or no intervention. However, caffeine appears to be safe.